The disclosure relates to macrocyclic picolinamides of Formula (I) and to the use of these compounds as fungicides.
本公开涉及式(I)的宏环吡啶酰胺,以及这些化合物作为杀菌剂的使用。
beta-DIHYDROFURAN DERIVING COMPOUND, METHOD FOR PRODUCING beta-DIHYDROFURAN DERIVING COMPOUND OR beta-TETRAHYDROFURAN DERIVING COMPOUND, beta-GLYCOSIDE COMPOUND, METHOD FOR PRODUCING beta GLYCOSIDE COMPOUND, AND METHOD FOR PRODUCING 4'-ETHYNYL D4T AND ANALOGUE COMPOUNDS THEREOF
申请人:Iriyama Yusuke
公开号:US20120322995A1
公开(公告)日:2012-12-20
The invention provides a process for producing a β-dihydrofuran derivative represented by formula (1) or a β-tetrahydrofuran derivative represented by formula (4), characterized in that the process includes causing a dialkyl dicarbonate, a diaralkyl dicarbonate, or a halide to act on a diol compound represented by formula (2) or (3). The invention also provides a process for producing 4′-ethynyl-2′,3′-didehydro-3′-deoxythymidine or an analog thereof, the process including glycosylation and deprotection.
METHOD OF PREPARING COMPLEX-AZO PIGMENT AND COMPLEX-AZO PIGMENT THEREOF
申请人:OHTA Masafumi
公开号:US20100010204A1
公开(公告)日:2010-01-14
A method of preparing a complex-azo pigment having plural pigment components including at least an azo pigment represented by the following formula (a)
A(H)n (a)
Pigments, both limited and unlimited by the process of making.
Method for the production of bicyclic aromatic amino acids and intermediate products thereof
申请人:Wiesner Matthias
公开号:US20060142568A1
公开(公告)日:2006-06-29
Process for the preparation of integrin inhibitors of the formula (I), in which R
1
, R
2
, R
3
, R
4
, R
5
and X have the meanings indicated in Claim
1
, and intermediate compounds.
ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS
申请人:Averett Devron R.
公开号:US20090298863A1
公开(公告)日:2009-12-03
This invention relates to methods for treating or preventing hepatitis C virus infections in mammals using Toll-Like Receptor (TLR)7 ligands and prodrugs thereof. More particularly, this invention relates to methods of orally administering a therapeutically effective amount of one or more prodrugs of TLR7 ligands for the treatment or prevention of hepatitis C viral infection. Oral administration of these TLR7 immunomodulating ligands and prodrugs thereof to a mammal provides therapeutically effective amounts and reduced undesirable side effects.